Back to all molecules
PreclinicalNot FDA-approved

5-Amino-1MQ

Small-molecule NNMT inhibitor; not a peptide

Also indexed as: NNMT inhibitor

What this evidence does not tell us

The cited study examines diet-induced obesity in mice, not weight loss in people.

Terms on this page

Unfamiliar word? Open this panel for simple explanations, right here.

5 glossary terms used in this profile

Select a word to see its meaning. You can keep more than one definition open.

Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.

Overview

5-Amino-1MQ is a synthetic small molecule studied as an inhibitor of the NNMT enzyme. It is included alongside peptides because of its metabolic-research context, but it is not a peptide.

Mechanism of action

NNMT / cellular metabolism

Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and methyl-donor metabolism. Experimental work asks how this changes adipose-cell metabolism.

A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.

Decode the terminology in our glossary

Scientific evidence

How strong is the evidence?

Early lab & animal research

  1. Limited evidence
  2. Early researchCurrent category
  3. Human research
  4. Human outcomes

Most support comes from cells or animals. These studies help form questions, but do not prove a treatment works in people.

For this research: The cited study examines diet-induced obesity in mice, not weight loss in people.

An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.

Cell studies

Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.

Animal experiments

The cited study investigates high-fat-diet-induced obesity in mice.

Human observational studies

Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.

Human clinical trials

Reliable, independently replicated human outcome evidence is not established by the selected sources in this edition.

Regulatory evidence

No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.

Potential research applications

Adipose metabolism and metabolic dysfunction in experimental models.

These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.

Explore research by health goal

Safety considerations

Human toxicology, drug interactions and long-term risks are not established. Effects on methylation and NAD metabolism require further study.

This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.

Regulatory status · United States

Not FDA-approved

No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.

Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.

Selected literature & source transparency

Cell / animal study· 2018

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.

Biochemical pharmacology

Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.

Continue your own source search

These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.

Three questions worth bringing to your clinician

  1. Which human outcomes—not just biomarkers—support this claim?
  2. What established options address my actual health concern?
  3. What do my medical history and current medicines change about the risks?

Beyond the library

Turn better questions into a thoughtful conversation.

Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.

Request an Optimization Consultation

Continue to our existing activation & intake page.

Education, not a prescription. Research summaries are not medical advice, dosing instructions, or an offer to sell. Mechanistic findings do not establish clinical effectiveness. US regulatory status is product- and indication-specific and may change. Discuss health decisions with a licensed clinician.